JonesTrading analyst Soumit Roy maintained a Buy rating on HCW Biologics (HCWB – Research Report) today and set a price target of $8.00. The company’s shares opened today at $1.47.
According to TipRanks, Roy is an analyst with an average return of -0.4% and a 30.20% success rate. Roy covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Monopar Therapeutics Inc, and Cassava Sciences.
HCW Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00, which is a 308.16% upside from current levels. In a report released on May 9, Maxim Group also reiterated a Buy rating on the stock with a $4.00 price target.
See today’s best-performing stocks on TipRanks >>
HCWB market cap is currently $55.27M and has a P/E ratio of -3.08.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HCW Biologics Inc is a preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases. It is developing HCW9218 as an injectable immunotherapeutic for patients with solid tumors.
Read More on HCWB:
- HCWB Upcoming Earnings Report: What to Expect?
- HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights
- HCW Biologics secures $26.25M non-dilutive financing
- HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
- HCW Biologics Poster Presentation at AACR Annual Meeting 2023
